DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for polymyalgia rheumatica — screening already-approved drugs against its 36-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePolymyalgia rheumatica maps to a 36-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for polymyalgia rheumatica is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Janus kinase 3 (JAK3) — JAK3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet izadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3LXL · 1.74 Å · ligand 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLINE-7-ONE (IZA). Experimental structure, not a prediction.
What the evidence adds up to
Polymyalgia rheumatica is an elderly-onset syndrome of aching and stiffness in the shoulders and pelvic girdle, with raised acute phase reactants and a rapid response to glucocorticoids. Its cause is unknown, but evidence points to a multifactorial, immune-mediated pathogenesis. One 2018 review argues that the disease fits best into the autoinflammatory end of the immune-mediated spectrum: symptoms often start over a few days or overnight, similar to periodic autoinflammatory disorders, and unlike the subacute onset of classic polygenic autoimmune diseases. After low-dose glucocorticoids, more than 40% of patients improve within 24–72 hours.
A 1999 editorial notes that survival in polymyalgia rheumatica is probably similar to the general population, and that neither malignant disease nor cardiovascular disorders appear to occur more often than expected. The main aim of treatment is symptomatic relief, and any benefit must be weighed against the risks of drug side effects. The editorial reviews oral corticosteroids, intramuscular and intravenous methylprednisolone, deflazacort, and methotrexate as therapeutic options. A 1990 article similarly discusses treatment but provides no new trial data.
No randomised controlled trial has yet established a non-glucocorticoid drug as a standard alternative. What is missing is a properly funded, placebo-controlled trial that stratifies patients by disease duration, inflammatory markers, and prior glucocorticoid exposure, and that measures sustained remission without steroid dependence. Without that, the evidence base remains limited to expert opinion and small case series.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
RMD Open · 2018 · 21 citations · open access
Polymyalgia rheumatica: an autoinflammatory disorder?
AbstractPolymyalgia rheumatica (PMR) is an elderly onset syndrome characterised by aching and stiffness in the shoulders and the pelvic girdle associated to increased levels of acute phase reactants and rapid response to glucocorticoids.1 Although the cause of PMR remains unknown, most of the evidence suggest a multifactorial aetiology inducing an immunomediated pathogenesis.1 2
According to the ‘immunological continuum model’ proposed by McGonagle in 2006, all immune-mediated diseases can be conceptualised as predominantly autoinflammatory, predominantly autoimmune or mixed, on the basis of the relative contributions of innate and adaptive immune responses.3 Autoinflammatory diseases (AIDs) are characterised by tissue inflammation mainly due to aberrant activation of innate immune system without autoantibodies production and autoreactive T lymphocyte activation. In contrast, autoimmune diseases (ADs) are typically depicted by an abnormal activation of the adaptive immune system.4 However, the emerging understanding of the close linkage between innate and adaptive immunity led to consider the rare monogenic AIDs and ADs as the two opposite ends into a continuum of immune-mediated disorders, where middle entities are recognised (figure 1).3
Figure 1
Simplified classification of immune-mediated disease by McGonagle and McDermott.3
In the view of this background, we tried to envisage the most suitable place for PMR into the spectrum of the autoinflammatory/autoimmune disorders by reviewing and interpreting current evidence.
Clear indication for a prevalent autoinflammatory background of PMR is related to the disease onset and course. Actually, starting of symptoms is generally over a few days or overnight in PMR,1 as well as in inflammatory periodic-recurring occurrence of AIDs,5 but in contrast to classic polygenic ADs where a subacute onset is frequently recorded (figure 2A).6 Further, after low-dose glucocorticoid therapy initiation, patients with PMR experience a rapid improvement of symptoms, generally within 24–72 hours, and more than 40% of them achieve …
Scandinavian Journal of Rheumatology · 1999 · 14 citations
Current therapy of polymyalgia rheumatica: EDITORIAL REVIEW
AbstractPolymyalgia rheumatica is characterized by muscular pain and stiffness developing almost exclusively in individuals older than 50 years. Most likely, survival is similar to that of the general population, and perceivably neither malignant diseases nor cardiovascular disorders occurs more frequently than expected. Thus, the main aim of treatment is symptomatic relief and the benefit of such interventions should always be weighed against the possible risks of drug induced side effects. The review addresses the therapeutic options in polymyalgia rheumatica, and focuses on oral corticosteroids, intramuscular and intravenous methylprednisolone, deflazacort, and methotrexate.
AbstractJournal Article Treatment of Polymyalgia Rheumatica Get access J. R. KIRWIN J. R. KIRWIN Rheumatology Unit, Department of Medicine, Bristol Royal InfirmaryBristol BS2 8HW Search for other works by this author on: Oxford Academic PubMed Google Scholar Rheumatology, Volume 29, Issue 4, August 1990, Pages 316–317, https://doi.org/10.1093/rheumatology/29.4.316-b Published: 01 August 1990 Article history Received: 26 April 1990 Published: 01 August 1990
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
